Revenue breakdown: Glaucoma (79.7%), Corneal Health (20.3%).
8-K
Glaukos Corporation announced record Q4 2025 net sales of $143.1 million, up 36% year-over-year, and full year 2025 net sales of $507.4 million, up 32% year-over-year, with a one-time non-cash impairment charge of $112.9 million impacting GAAP results. The company reaffirmed 2026 net sales guidance of $600 million to $620 million.